[The modern organ- and function-sparing surgical treatment in oncology].
The results of organ-sparing treatment of patients with cancers of the breast, uterine cervix, endometrium and ovary are described in the paper. A prospective randomized clinical study launched in 1995 at Petrov's Research Institute of Oncology comprised cases of above 700 patients with breast cancer, around 300 women with cancer in situ and with microinvasive cancer of the uterine cervix and 83 patients with initial endometrial cancer. The results of the above treatment (segment resection + axillar dissection + radiotherapy) were shown to be similar to those obtained after Petey-Dyson mastectomy (5-year survival of 86.7% versus 88.8%, p = 0.81). The risk of local recurrence was increasing in patients with the tumors' diameter of more than 1 cm who were not treated by radiotherapy. The total regression of tumors was registered in 70% of patients with initial endometrial cancer after hormone therapy by progestagens and antiestrogens; 20% of them maintained the reproductive function.
Semiglazov
V F
VF
Maksimov
S Ia
SIa
Semiglazov
V V
VV
Kosnikov
A G
AG
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004598:Electrosurgery; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007044:Hysterectomy; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008408:Mastectomy; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D011182:Postoperative Care; D011372:Progestins / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*
D020847:Estrogen Receptor Modulators; D011372:Progestins; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate